542 related articles for article (PubMed ID: 26399371)
21. SURGICAL OUTCOMES OF PROLACTINOMAS IN RECENT ERA: RESULTS OF A HETEROGENOUS GROUP.
Donegan D; Atkinson JL; Jentoft M; Natt N; Nippoldt TB; Erickson B; Meyer F; Erickson D
Endocr Pract; 2017 Jan; 23(1):37-45. PubMed ID: 27682355
[TBL] [Abstract][Full Text] [Related]
22. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
[TBL] [Abstract][Full Text] [Related]
23. Prolactinomas in males: any differences?
Duskin-Bitan H; Shimon I
Pituitary; 2020 Feb; 23(1):52-57. PubMed ID: 31802331
[TBL] [Abstract][Full Text] [Related]
24. [Indications for surgical treatment of prolactin-secreting pituitary adenomas].
Kalinin PL; Astaf'eva LI; Kadashev BA; Ismailov DB
Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(5):117-124. PubMed ID: 29076475
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
26. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
Manuchehri AM; Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
Pituitary; 2007; 10(3):261-6. PubMed ID: 17557207
[TBL] [Abstract][Full Text] [Related]
27. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
28. The safety of treatments for prolactinomas.
Auriemma RS; Grasso LF; Pivonello R; Colao A
Expert Opin Drug Saf; 2016; 15(4):503-12. PubMed ID: 26855238
[TBL] [Abstract][Full Text] [Related]
29. [Prolactinoma].
Glezer A; Bronstein MD
Arq Bras Endocrinol Metabol; 2014 Mar; 58(2):118-23. PubMed ID: 24830588
[TBL] [Abstract][Full Text] [Related]
30. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
31. Giant Prolactinomas.
Shimon I
Neuroendocrinology; 2019; 109(1):51-56. PubMed ID: 30404098
[TBL] [Abstract][Full Text] [Related]
32. Dopamine agonists and pituitary tumor shrinkage.
Bevan JS; Webster J; Burke CW; Scanlon MF
Endocr Rev; 1992 May; 13(2):220-40. PubMed ID: 1352243
[TBL] [Abstract][Full Text] [Related]
33. Giant prolactinomas: are they really different from ordinary macroprolactinomas?
Espinosa E; Sosa E; Mendoza V; Ramírez C; Melgar V; Mercado M
Endocrine; 2016 Jun; 52(3):652-9. PubMed ID: 26561015
[TBL] [Abstract][Full Text] [Related]
34. Prolactinomas: how to handle prior to and during pregnancy?
Glezer A; Bronstein MD
Minerva Endocrinol; 2018 Dec; 43(4):423-429. PubMed ID: 29265784
[TBL] [Abstract][Full Text] [Related]
35. Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma).
Berezin M; Shimon I; Hadani M
J Endocrinol Invest; 1995 Jun; 18(6):436-41. PubMed ID: 7594238
[TBL] [Abstract][Full Text] [Related]
36. Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment.
Shimon I
Arch Med Res; 2023 Dec; 54(8):102883. PubMed ID: 37689507
[TBL] [Abstract][Full Text] [Related]
37. Combined treatment of invasive giant prolactinomas.
Yu C; Wu Z; Gong J
Pituitary; 2005; 8(1):61-5. PubMed ID: 16411070
[TBL] [Abstract][Full Text] [Related]
38. Approach to the Patient With Prolactinoma.
Auriemma RS; Pirchio R; Pivonello C; Garifalos F; Colao A; Pivonello R
J Clin Endocrinol Metab; 2023 Aug; 108(9):2400-2423. PubMed ID: 36974474
[TBL] [Abstract][Full Text] [Related]
39. Giant prolactinomas: clinical management and long-term follow up.
Shrivastava RK; Arginteanu MS; King WA; Post KD
J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
[TBL] [Abstract][Full Text] [Related]
40. [Prolactinoma].
Krysiak R; Okopień B; Marek B; Szkróbka W
Przegl Lek; 2009; 66(4):198-205. PubMed ID: 19708510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
